Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779675 | 0.87 | S1PR3 (0.53) | S1PR3MAPT | |
| SCHEMBL5773330 | 0.80 | MAPT (0.56) | S1PR3TP53MAPT | |
| SCHEMBL4916084 | 0.72 | CCR3 (0.43) | HPGDMAPT | |
| SCHEMBL3846422 | 0.71 | TUBB4A (0.53) | — | |
| SCHEMBL6255149 | 0.69 | TUBB4A (0.48) | TP53MAPTLMNA | |
| SCHEMBL14972834 | 0.67 | MAPT (0.43) | S1PR3TP53MAPTHTTLMNA | |
| SCHEMBL2160503 | 0.67 | FAAH (0.50) | TP53MAPTNPC1RAB9ALMNA | |
| SCHEMBL2168842 | 0.65 | FAAH (0.64) | TP53HPGDMAPT | |
| SCHEMBL3847524 | 0.65 | FAAH (0.54) | TP53HPGDMAPTSMN1; SMN2LMNA | |
| SCHEMBL14972847 | 0.62 | MAPT (0.47) | TP53MAPTHTTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579365-B2 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ZIOPHRAM ONCOLOGY, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20030023093-A1 | United states patent office | ASTA MEDICA AKTIENGESELLSCHAFT | 2003-01-30 | — | — | US | disclosed |
| US-6232327-B1 | AND PHYSIOLOGICALLY TOLERABLE ACID ADDITION SALTS, N-OXIDES | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023093-A1 | United states patent office | IDO1, IDO2, TDO2 | ROCK2 3744/4885S1PR3 1448/4885TP53 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.